{ "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 71, "pageCount": 74, "prevPage": 70, "nextPage": 72, "slideType": "problem_statement", "function": "diagnose_problem", "density": "overcrowded", "nDataPoints": 4, "notes": "Includes a causal flow diagram showing the link between achieving a 38% return and specific 2030 financial outcomes.", "elementsJson": [ "headline_text", "bullet_list", "process_diagram", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/71", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckJsonHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3.json", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-71", "components": [ { "bbox": null, "kind": "callout", "text": "The Board is responsible for holding management accountable on improving its expected revenue return to at least 38%", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd952-e6ec-7186-b7bf-42b28494a0dc", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.64, "x": 0.18, "y": 0.7 }, "kind": "diagram", "text": "Achieving at least 38% expected 2030 revenue return... ... Would result in 2030 Sales of $79bn and Adj. EPS of >$4.25", "attrs": null, "subkind": "process", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "c67c1174-fc5a-486e-b3b7-e37c24719faa", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.55, "w": 0.92, "x": 0.04, "y": 0.16 }, "kind": "list", "text": "We agree with management: “the operational measurement of success will be [Pfizer’s] ability to have a constant flow of breakthrough innovation”\nUnderlying Pfizer’s ability to produce consistent innovation is its ability to generate attractive revenue returns on its R&D and M&A investments\nManagement is allocating a substantial amount of shareholder capital\nTo-date, the Company has not achieved sufficient revenue returns on R&D and M&A\nThe Company is expected to generate revenue returns of just 15% compared to the peer median of 38%\nPfizer ranks worst-in-class among its peer group on expected gross revenue growth from 2023 to 2030 based on its cumulative R&D and M&A from 2019 to 2023\nCapital allocation and M&A is critically important to pharma companies – Pfizer has been worst-in-class\nThe Board is responsible for holding management accountable on improving its expected revenue return to at least 38%", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "5a61f977-4833-478c-9a7d-a8f81a988f07", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "metric", "text": "revenue returns: 38%", "attrs": null, "subkind": "primary", "toolName": "Quantification", "toolSlug": "quantification", "confidence": null, "componentId": "019dd952-e6ec-7186-b7bf-4b9e0cc84922", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "We agree with management: “the operational measurement of success will be [Pfizer’s] ability to have a constant flow of breakthrough innovation” — Pfizer Management", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd952-e6ec-7186-b7bf-471b28194c77", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.35, "x": 0.01, "y": 0.97 }, "kind": "source-note", "text": "Source: Public company filings, Wall Street Research, and Starboard estimates. (1) Excluding COVID.", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "d35328a8-5ba8-479e-a284-533284b8707d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.92, "x": 0.04, "y": 0.89 }, "kind": "title", "text": "The Board needs to hold management accountable for improving performance.", "attrs": null, "subkind": "action-title", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "e30cd6fd-01e5-4318-8409-789516cbd315", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.92, "x": 0.04, "y": 0.03 }, "kind": "title", "text": "The Board Needs to Hold Management Accountable For Achieving Sufficient Revenue Returns on R&D and M&A", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "45ad9c7e-15ea-498b-8864-eea257acfd54", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [ { "name": "causal-chain", "slug": null, "matchId": "74911945-e87d-45aa-a2a3-3d7501f8eb79", "evidence": "The diagram at the bottom links the 38% return target to specific 2030 financial outcomes.", "confidence": 0.9 } ], "arcBeats": [ { "to": 73, "from": 62, "beatId": "a59926c3-5c53-408e-b52d-295dfb9b624a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document proposes potential solutions, including focusing on R&D and innovation, improving capital allocation, and holding management accountable.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "loops": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" }, { "to": 73, "from": 62, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "c59431c8-0af0-4e90-9758-ec528e713b8a", "evidence": "The document highlights potential areas for improvement and growth.", "position": 2, "objective": "What are the potential quick wins and big bets for Pfizer?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }